AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8067499
Drug: Propranolol, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 60 mg or less, administered daily between 5:30 and 6:00 a.m.
Trial: 3052917
Drug: GIK cardioplegic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK cardioplegic solution with calcium and PGI2 analogue (OP-41483, 300 micrograms/l)
Trial: 3052917
Drug: GIK cardioplegic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK cardioplegic solution with calcium (1.2 mM)
Trial: 3052917
Drug: Basic GIK
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic GIK cardioplegic solution alone (no added calcium)
Trial: 31597806
Drug: Curcumin gel
DrugBank: Curcumin sulfate (DB14635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin gel applied post-scaling and root planing (SRP)
Trial: 31597806
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no curcumin gel)
Trial: 28283490
Drug: GOPC medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOPC medical treatment orders
Trial: 24625625
Drug: Tanezumab monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab monotherapy (5 or 10 mg)
Trial: 24625625
Drug: Tanezumab +
RxNorm normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab + NSAIDs (naproxen 500 mg twice daily or celecoxib 100 mg twice daily)
Trial: 24625625
Drug: Tanezumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab (5 or 10 mg)
Trial: 21982649
Drug: Canakinumab (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (50, 150, or 300 mg every 3 months, administered subcutaneously)
Trial: 19238654
Drug: gemfibrozil 1200
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gemfibrozil 1200 mg
Trial: 26539650
Drug: atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin 40 mg
Trial: 10882574
Drug: Enhanced‐potency inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced‐potency inactivated poliovirus vaccine (E‐IPV) followed by monovalent oral poliovirus vaccine (OPV, type 3 Sabin)
Trial: 8807623
Drug: Disodium monofluorophosphate
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium monofluorophosphate (MFP) 13.2 mg/day + calcium (1,000 mg/day) + calcifediol (50 micrograms/day)
Trial: 8807623
Drug: Calcium (1,000
RxNorm normalized name: calcium carbonate 390 mg calcium (1,000 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1,000 mg/day) + calcifediol (50 micrograms/day)
Trial: 6586292
Drug: Interferon-alpha A
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha A (1 ng/ml)
Trial: 6586292
Drug: Interferon-alpha D
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha D (1 ng/ml)
Trial: 27117223
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 2000 ml/h
Trial: 27117223
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 1000 ml/h
Trial: 27117223
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 500 ml/h
Trial: 20061913
Drug: Steroid avoidance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid avoidance or withdrawal (SAW)
Trial: 11085964
Drug: Nitroglycerin (sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (sublingual administration)
Trial: 11973410
Drug: NG‐monomethyl‐l‐arginine (infusion)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG‐monomethyl‐l‐arginine (infusion)
Trial: 10962387
Drug: triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triple therapy + ranitidine (n = 180)
Trial: 10962387
Drug: triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triple therapy alone (n = 163)
Trial: 10962387
Drug: triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triple therapy + ranitidine
Trial: 10962387
Drug: triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triple therapy alone
Trial: 12361129
Drug: 2% erythromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% erythromycin gel
Trial: 1600584
Drug: 0.6 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 micrograms yeast-derived hepatitis B vaccine
Trial: 1600584
Drug: 1.25 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 micrograms yeast-derived hepatitis B vaccine
Trial: 1600584
Drug: 2.5 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 micrograms yeast-derived hepatitis B vaccine
Trial: 1600584
Drug: 5.0 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 micrograms yeast-derived hepatitis B vaccine
Trial: 1600584
Drug: All dosages
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dosages of yeast-derived hepatitis B vaccine
Trial: 6230611
Drug: Electronic infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electronic infusion controller (IVAC 230)
Trial: 6230611
Drug: Standard infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard infusion method (control group)
Trial: 29526749
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of Oxytocin
Trial: 12768912
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of eptifibatide
Trial: 10597554
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (3 micrograms.kg‐1.min‐1) (Group A)
Trial: 10597554
Drug: Dextrose infusion
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose infusion (control) (Group B)
Trial: 8605791
Drug: 11 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 ppm inhaled nitric oxide
Trial: 8605791
Drug: 60 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 ppm inhaled nitric oxide
Trial: 11435053
Drug: 40 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ppm inhaled nitric oxide
Trial: 9367476
Drug: 10 ppm
RxNorm normalized name: Glycerin 1.0 g in 25 mL TOPICAL CREAM [EGF Crystal 10 ppm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ppm inhaled nitric oxide
Trial: 29766634
Drug: Comparators (placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparators (placebo, sitagliptin, exenatide extended release, insulin glargine)
Trial: 26251112
Drug: Reminiscence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminiscence therapy (30-35 minutes, once a week for 12 weeks)
Trial: 26251112
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no reminiscence therapy)
Trial: 24025983
Drug: Mericitabine 500
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mericitabine 500 mg
Trial: 24025983
Drug: Mericitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mericitabine 1000 mg
Trial: 24025983
Drug: Mericitabine 2000
RxNorm normalized name: gemcitabine 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mericitabine 2000 mg
Trial: 24025983
Drug: Mericitabine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mericitabine (all doses)
Trial: 10897159
Drug: LEV 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV 1,000 mg
Trial: 15679515
Drug: LEV 333
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Uni-Lev 5.0]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEV 333 mg
Trial: 2669119
Drug: Omeprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (30 mg)
Trial: 2669119
Drug: Cimetidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1 g)
Trial: 353659
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose heparin (t.i.d.)
Trial: 353659
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose heparin (t.i.d.) combined with aspirin
Trial: 11802037
Drug: Intranasal azelastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal azelastine
Trial: 23834132
Drug: Isotonic sea
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic sea water nasal spray
Trial: 9360699
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of fibrin glue added to peritoneal cuff suture
Trial: 2886245
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg famotidine
Trial: 1544289
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg quinidine
Trial: 4054204
Drug: Cianergoline (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cianergoline (maximum daily dose 12 +/- 2 mg for 4 weeks)
Trial: 30269640
Drug: Automated telemedicine
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated telemedicine intervention (daily phone messages with proactive alerts)
Trial: 30269640
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily phone messages without proactive alerts)
Trial: 29914666
Drug: 800 mg/d
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg/d resveratrol for 8 weeks
Trial: 22994055
Drug: Compound Xuanju
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Xuanju Capsule
Trial: 22994055
Drug: Antibiotics (Control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (Control)
Trial: 16293868
Drug: Single-agent gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent gemcitabine (G arm)
Trial: 396055
Drug: Praziquantel 3
RxNorm normalized name: praziquantel 34 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 3 x 20 mg/kg
Trial: 396056
Drug: Praziquantel 1
RxNorm normalized name: praziquantel 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 1 x 50 mg/kg
Trial: 30948756
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg L-DOPA (low-weight participants)
Trial: 30265586
Drug: Early diagnosis
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early diagnosis and treatment of glucocorticoid-induced adverse events
Trial: 28069040
Drug: Acupuncture, electroacupuncture,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture, electroacupuncture, and intradermal acupuncture (6 sessions within 8 days starting within 48 hours of craniotomy)
Trial: 25886483
Drug: Acupuncture, electroacupuncture,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture, electroacupuncture, and intradermal acupuncture
Trial: 21893447
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg/d) for six weeks
Trial: 12623744
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 mg) and selenium (225 microg) supplementation for 3 months
Trial: 12623744
Drug: Vitamin B
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B (4.5 g/day) for 3 months
Trial: 15096005
Drug: Intravenous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous therapy with continuous IGF‐I (0.01 mg/kg/hour)
Trial: 8437596
Drug: High-dose carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose carboplatin alone (800 mg per square meter)
Trial: 26919410
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg s.c. at baseline, week 1, 2, 3, and 4, then every 4 weeks (with up-titration to 300 mg for 2 non-responders)
Trial: 20231321
Drug: No-dose-reduction group
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-dose-reduction group (initial optimal therapeutic dose continued throughout the study)
Trial: 20231321
Drug: 4-week group
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week group (initial optimal therapeutic dose continued for 4 weeks, followed by a 50% dose reduction)
Trial: 20231321
Drug: 26-week group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26-week group (initial optimal therapeutic dose continued for 26 weeks, followed by a 50% dose reduction)
Trial: 18341673
Drug: Brivaracetam 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam 800 mg/day
Trial: 10606361
Drug: Synacthen depot
RxNorm normalized name: Synacthen Depot
DrugBank: Tetracosactide (DB01284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synacthen depot 0.5 mg on alternate days for 2 injections
Trial: 2840279
Drug: Guar biscuit
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar biscuit (2.9 g of guar)
Trial: 2840279
Drug: Guar biscuit
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar biscuit (6.0 g of guar)
Trial: 2840279
Drug: Guar biscuit
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar biscuit (9.1 g of guar)
Trial: 21878067
Drug: Coenzyme Q(10)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coenzyme Q(10) in combination with enalapril
Trial: 15478524
Drug: Midodrine 10
RxNorm normalized name: midodrine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine 10 mg
Trial: 9674789
Drug: Midodrine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine 20 mg
Trial: 9674789
Drug: Midodrine (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (2.5, 10, or 20 mg)
Trial: 8072201
Drug: Neoadjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant endocrine therapy followed by surgery
Trial: 8072201
Drug: Neoadjuvant endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant endocrine therapy followed by irradiation
Trial: 12525260
Drug: Maca 1500
RxNorm normalized name: MACA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maca 1500 mg
Trial: 12525260
Drug: Maca 3000
RxNorm normalized name: MACA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maca 3000 mg
Trial: 26355167
Drug: 4.0 mm-long
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 mm-long implants
Trial: 27990507
Drug: 10 mm
RxNorm normalized name: potassium 10 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mm or longer implants in augmented bone
Trial: 27990507
Drug: Short implants
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short implants (4.0 mm)
Trial: 27990507
Drug: 10 mm
RxNorm normalized name: potassium 10 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mm or longer mandibular implants
Trial: 25738177
Drug: Short maxillary
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short maxillary implants
Trial: 27990507
Drug: 10 mm
RxNorm normalized name: potassium 10 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mm or longer maxillary implants
Trial: 27990507
Drug: Augmented group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented group (10 mm or longer implants)
Trial: 23327881
Drug: Tacrolimus (Tac)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (Tac) administered once daily at a dose of 3 mg
Trial: 11823664
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy (biweekly intravenous alpha-galactosidase A infusions)
Trial: 10369625
Drug: Once-daily aminoglycosides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily aminoglycosides (ODA)
Trial: 10369625
Drug: Conventional dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosing of aminoglycosides
Trial: 7771004
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 monotherapy (20 micrograms)
Trial: 7771004
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Prostaglandin E1 20 micrograms plus lidocaine 1% 1 cc)
Trial: 2335312
Drug: Induction with
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction with oxytocin infusion
Trial: 24445833
Drug: Inactivated quadrivalent
RxNorm normalized name: influenza virus vaccine, inactivated quadrivalent intramuscular suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated quadrivalent influenza vaccine (QIV)
Trial: 26336604
Drug: Trivalent control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent control vaccine (TIV)
Trial: 8615362
Drug: High-resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-resistant starch (39 +/- 3 g/d)
Trial: 8615362
Drug: Low-resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-resistant starch (5 +/- 0.4 g/d)
Trial: 1351126
Drug: HDC (6.52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDC (6.52 international potency units per dose)
Trial: 3969876
Drug: Bretylium 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bretylium 2.5 mg/kg over 60 minutes
Trial: 3969876
Drug: Bretylium 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bretylium 5.0 mg/kg over 60 minutes
Trial: 3969876
Drug: Bretylium 10
RxNorm normalized name: bretylium 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bretylium 10 mg/kg over 60 minutes
Trial: 24690964
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (2.5 g per day of eicosapentaenoic + docosahexaenoic)
Trial: 17661245
Drug: Morning preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning preparation
Trial: 17661245
Drug: Evening preparation
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening preparation
Trial: 16128276
Drug: Genetically derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically derived vaccine (20 microg)
Trial: 16128276
Drug: Plasma pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma pooled vaccine (3 microg)
Trial: 9846796
Drug: Chlorhexidine (0.12%)
RxNorm normalized name: chlorhexidine 12 MG
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (0.12%) and Perborate (1.9 g sodium perborate-monohydrate in 30 ml water)
Trial: 8003060
Drug: Amoxicillin plus
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin plus probenecid for 30 days
Trial: 2553364
Drug: UFTM (UFT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFTM (UFT and mitomycin C); UFT: 30 g total dose, Mitomycin C: 48-60 mg total dose
Trial: 30650418
Drug: Early palliative
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early palliative care intervention (monthly intervention by palliative care specialists at home for 12 months)
Trial: 21859900
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (AC) with gemcitabine 1000 mg/m² on days 1, 8, and 15 and cisplatin 70 mg/m² on day 2, every 28 days.
Trial: 21859900
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (AC) with gemcitabine and cisplatin as above.
Trial: 21859900
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (AC) with cisplatin on day 2.
Trial: 11473839
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine (6 to 10 mL of 0.25% bupivacaine epidurally, followed by infusion at 3 to 5 mL/h for 3 days)